Now Available, Veeva Falcon MLR Delivers Agentic MLR™<\/sup> <\/i><\/p>\n \nPLEASANTON, Calif. and COPENHAGEN, Denmark \u2014 June 23, 2026 \u2014 <\/strong> Veeva Systems<\/a> (NYSE: VEEV) today announced it has acquired Copli, the pioneer in agentic medical, legal, and regulatory (MLR) solutions for the life sciences industry. Copli is now available as Veeva Falcon MLR, an agentic MLR solution that significantly accelerates content review with the potential to eliminate 70% or more of manual MLR labor within five years.\n<\/p>\n \nVeeva Falcon MLR brings agentic automation to marketing teams, MLR groups, and agencies. It executes rigorous reviews of promotional and medical materials, conducting compliance checks against approved labels and local regulations, to minimize manual effort and free reviewers for higher value work.\n<\/p>\n \n\u201cOur breakthrough with agentic MLR marks a fundamental shift in commercial and medical content review and approval,\u201d said Jacob Scheel-Bech, CEO of Copli. \u201cAs part of Veeva, we can scale our vision for MLR transformation. Veeva Falcon MLR brings compliance at speed to the industry with intelligent agents that work seamlessly with Veeva PromoMats.\u201d\n<\/p>\n \n\u201cThe MLR process has long been a significant bottleneck in getting critical information to patients and doctors,\u201d said Emma Hyland, vice president, Veeva Commercial Content. \u201cWith Veeva Falcon MLR, our customers can speed up the entire review cycle, automating routine labor so reviewers can become strategic advisors.\u201d\n<\/p>\n \nTo learn more about Veeva Falcon MLR register for the upcoming webinar<\/a> on July 9 at 10 a.m. ET or visit FalconMLR.veeva.com<\/a>.\n<\/p>\n About Veeva Systems<\/strong> Veeva Forward-Looking Statements<\/strong> \nContact:<\/strong>\n<\/p>\n \nMaria Scurry
to Significantly
\nReduce Manual Effort and Shorten Review Cycles<\/p>\n
\nVeeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com<\/a>.\n<\/p>\n
\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.\n<\/p>\n
\nVeeva Systems
\nmaria.scurry@veeva.com<\/a>\n<\/p>\n